Nakamura, K.; Aimono, E.; Tanishima, S.; Imai, M.; Nagatsuma, A.K.; Hayashi, H.; Yoshimura, Y.; Nakayama, K.; Kyo, S.; Nishihara, H.
Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma. Diagnostics 2020, 10, 200.
https://doi.org/10.3390/diagnostics10040200
AMA Style
Nakamura K, Aimono E, Tanishima S, Imai M, Nagatsuma AK, Hayashi H, Yoshimura Y, Nakayama K, Kyo S, Nishihara H.
Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma. Diagnostics. 2020; 10(4):200.
https://doi.org/10.3390/diagnostics10040200
Chicago/Turabian Style
Nakamura, Kohei, Eriko Aimono, Shigeki Tanishima, Mitsuho Imai, Akiko Kawano Nagatsuma, Hideyuki Hayashi, Yuki Yoshimura, Kentaro Nakayama, Satoru Kyo, and Hiroshi Nishihara.
2020. "Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma" Diagnostics 10, no. 4: 200.
https://doi.org/10.3390/diagnostics10040200
APA Style
Nakamura, K., Aimono, E., Tanishima, S., Imai, M., Nagatsuma, A. K., Hayashi, H., Yoshimura, Y., Nakayama, K., Kyo, S., & Nishihara, H.
(2020). Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma. Diagnostics, 10(4), 200.
https://doi.org/10.3390/diagnostics10040200